Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session

Kelun-Biotech's sacituzumab tirumotecan (sac-TMT) will have three Phase III studies presented as late-breaking abstracts at ESMO 2026, including OptiTROP-Lung04 and Lung06 in metastatic NSCLC and TroFuse-005 in previously treated endometrial cancer. The lung studies include final overall-survival data in EGFR-mutated NSCLC and a first-line PD-L1-negative NSCLC comparison of sac-TMT plus pembrolizumab versus chemotherapy plus pembrolizumab. The ESMO selections increase visibility ahead of potentially material clinical readouts for Kelun and global ex-China partner MSD, which has 18 ongoing global Phase III sac-TMT studies.

Analysis

For MRK, the commercial relevance is less the near-term economics of a licensed asset and more whether sac-TMT can extend the pembrolizumab treatment ecosystem into settings where chemotherapy remains the default. A credible first-line PD-L1-negative NSCLC result would create a differentiated chemo-sparing or chemo-reducing narrative, potentially defending MRK's lung-cancer franchise against post-LOE erosion; however, the incremental revenue is unlikely to move consolidated FY27 estimates until regulatory filings, label scope, and ex-China profit-sharing terms are visible.

The October 25 readouts are binary clinical catalysts, not validation merely because of their conference placement. The key investable variables are hazard ratios, median overall survival maturity, discontinuation rates, and grade 3+ neutropenia/diarrhea relative to chemo-based standards. Strong efficacy with manageable toxicity would pressure GILD's Trodelvy positioning and raise the competitive bar for AZN/DAI's datopotamab deruxtecan program; a marginal benefit or high discontinuation rate would reinforce the view that TROP2 ADCs remain difficult to move into broad first-line populations.

Consensus may over-credit a positive study for MRK because its market capitalization dilutes even a major oncology opportunity. The more asymmetric vehicle is 6990.HK, whose valuation should be highly sensitive to evidence that its ADC platform can produce registrational wins across tumor types, although this also carries concentrated single-asset, China reimbursement, and liquidity risk. Over the next 1-3 months, abstract release and full ESMO data should drive probabilities; over 6-18 months, FDA/EMA regulatory strategy and global launch sequencing—not headline clinical success alone—determine monetization.

Falsification for the constructive thesis is a non-competitive OS result, weak PFS durability, or toxicity that prevents sustained dosing in the combination arm. Even positive data would not justify an MRK rerating if management characterizes the asset as immaterial to long-range growth, if royalty economics are modest, or if competing TROP2 programs report superior benefit-risk before filing.

Key Decisions for Investors

• Maintain MRK as a watch, not a standalone event long, into October 25: the company-level earnings sensitivity is too diluted for favorable risk/reward absent evidence of material disclosed royalty or milestone exposure. Reassess only if full data support a broad first-line label and MRK quantifies global commercial contribution.
• For biotech-capable capital, consider a small, defined-risk long 6990.HK position 1-2 weeks before ESMO only after confirming local borrow/liquidity and the abstract's efficacy endpoints; target a 2-3x payoff versus a pre-defined 10-15% stop. Do not size as a core position because negative safety or OS data can cause a substantially larger gap-down.
• Use AZN and GILD as competitive read-through alerts rather than immediate shorts: a clearly superior benefit-risk profile for sac-TMT in NSCLC would weaken differentiation for Dato-DXd and Trodelvy, but cross-trial comparisons are insufficient. Escalate to relative-value positioning only after dose intensity, discontinuations, and biomarker-subgroup outcomes are available.
• At the data release, prioritize an MRK/large-cap oncology basket over a directional market bet: add MRK only if OS is mature and toxicity supports routine community use; fade any initial MRK strength if results are PFS-only, immature, or dependent on a narrow subgroup.